PLX Logo

Protalix BioTherapeutics, Inc. (PLX) 

AMEX
Market Cap
$125.55M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
379 of 775
Rank in Industry
202 of 433

Largest Insider Buys in Sector

PLX Stock Price History Chart

PLX Stock Performance

About Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a …

Insider Activity of Protalix BioTherapeutics, Inc.

Over the last 12 months, insiders at Protalix BioTherapeutics, Inc. have bought $0 and sold $0 worth of Protalix BioTherapeutics, Inc. stock.

On average, over the past 5 years, insiders at Protalix BioTherapeutics, Inc. have bought $167,854 and sold $2.09M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 64,516 shares for transaction amount of $90,484 was made by Bashan Dror (PRESIDENT AND CEO) on 2023‑10‑19.

List of Insider Buy and Sell Transactions, Protalix BioTherapeutics, Inc.

2023-10-19PurchasePRESIDENT AND CEO
64,516
0.0878%
$1.40$90,484-13.79%
2023-01-03Purchasedirector
110,000
0.1979%
$1.42$155,815+30.97%
2022-04-11PurchasePresident and CEO
68,000
0.1528%
$1.50$102,000-19.15%
2021-06-03Sale10 percent owner
857,506
1.9156%
$2.25$1.93M-48.20%
2021-06-02Sale10 percent owner
61,211
0.1389%
$2.56$156,553-53.63%
2020-04-07Purchasedirector
64,000
0.1994%
$2.43$155,264+53.33%
2017-05-16PurchasePresident & CEO
50,000
0.0383%
$0.81$40,500-20.48%
2016-12-02Sale10 percent owner
2.5M
2.5199%
$0.32$792,000+145.16%
2015-12-14PurchaseVice President & CFO
10,000
0.01%
$0.78$7,800-2.56%
2015-10-19Purchase10 percent owner
4M
4.0937%
$1.00$4M-18.37%
2014-08-13Sale
4.4M
4.4447%
$2.47$10.87M-21.67%
2014-08-13Sale10 percent owner
4.4M
4.4447%
$2.47$10.87M-21.67%
2013-08-15Saledirector
2,330
0.0025%
$5.07$11,813-14.98%
2013-08-14Saledirector
110,000
0.1193%
$5.05$555,750-14.78%
2013-03-12Saledirector
10,000
0.0108%
$5.70$57,000-12.63%
2013-03-11Saledirector
18,300
0.0198%
$5.72$104,737-12.63%
2013-03-08Saledirector
16,898
0.0182%
$5.86$99,068-14.94%
2013-03-07Saledirector
8,435
0.0092%
$5.72$48,233-12.17%
2013-03-06Saledirector
4,700
0.0051%
$5.69$26,737-11.71%
2012-05-02SaleExecutive VP, R&D
300,000
0.3334%
$7.13$2.14M-20.83%

Insider Historical Profitability

<0.0001%
Camber Capital Management LLC10 percent owner
10775000
14.6333%
$1.7111<0.0001%
FROST PHILLIP MD ET AL10 percent owner
7610167
10.3352%
$1.71225+14.01%
Shaaltiel YosephExecutive VP, R&D
463754
0.6298%
$1.71416<0.0001%
Schwartz Aharondirector
174000
0.2363%
$1.7120+42.15%
Bashan DrorPRESIDENT AND CEO
132516
0.18%
$1.7120<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$4.17M4.513.31M-4.26%-$185,493.40<0.0001
State Street$1.04M1.13826,5810%+$0<0.0001
Renaissance Technologies$1.04M1.13824,700+23.9%+$200,442.46<0.01
Geode Capital Management$950,178.001.03754,110+4.08%+$37,214.08<0.0001
Gsa Capital Partners Llp$622,000.000.67493,571-9.31%-$63,850.740.05
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.